Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Pyritidium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | BLM | P54132 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | APAF1 | O14727 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | TERT | O14746 | 5/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | THRB | P10828 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | CASP1 | P29466 | 3/20 | 0.36 |
| ▸ | RECQL | P46063 | 3/20 | 0.36 |
| ▸ | CASP7 | P55210 | 3/20 | 0.36 |
| ▸ | MITF | O75030 | 2/20 | 0.36 |
| ▸ | NSD2 | O96028 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyritidium SCHEMBL30468818 | 1.00 | MEN1 (0.51) | MEN1BLMKMT2AAPAF1NPC1 | |
| Pyritidium SCHEMBL29387282 | 0.99 | MEN1 (0.49) | MEN1BLMKMT2AAPAF1NPC1 | |
| Pyritidium SCHEMBL7636972 | 0.98 | MEN1 (0.49) | MEN1BLMKMT2AAPAF1NPC1 | |
| SCHEMBL291198 | 0.73 | TERT (0.67) | MEN1BLMKMT2ANPC1RAB9A | |
| Bromide SCHEMBL592713 | 0.69 | MEN1 (1.00) | MEN1BLMKMT2AAPAF1NPC1 | |
| Water SCHEMBL864813 | 0.68 | MEN1 (0.97) | MEN1BLMKMT2AAPAF1NPC1 | |
| Sulfuric Acid SCHEMBL8658789 | 0.68 | TERT (0.59) | MEN1BLMKMT2ATERTALOX15 | |
| SCHEMBL26848576 | 0.67 | MEN1 (0.97) | MEN1BLMKMT2AAPAF1NPC1 | |
| SCHEMBL2014260 | 0.67 | MEN1 (0.97) | MEN1BLMKMT2AAPAF1NPC1 | |
| Iodide SCHEMBL9380644 | 0.67 | ROCK1 (0.52) | MEN1KMT2ANPC1POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4408854-B1 | NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF PARASITIC INFECTIONS | UNIV ANTWERPEN (BE) | 2026-04-22 | — | — | EP | disclosed |
| US-20250320245-A1 | Nucleoside Analogues for the Treatment of Parasitic Infections | UNIVERSITEIT ANTWERPEN (BE) | 2025-10-16 | — | — | US | disclosed |
| EP-4408854-A1 | NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF PARASITIC INFECTIONS | Universiteit Antwerpen (BE) | 2024-08-07 | — | — | EP | disclosed |
| WO-2023052468-A1 | NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF PARASITIC INFECTIONS | UNIVERSITEIT ANTWERPEN (BE) | 2023-04-06 | — | — | WO | disclosed |
| US-8454582-B2 | Methods and devices for the treatment of ocular conditions | SURMODICS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110159073-A1 | METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS | DEJUAN EUGENE | 2011-06-30 | — | — | US | disclosed |
| WO-2008021210-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| US-20060110428-A1 | Methods and devices for the treatment of ocular conditions | SURMODICS MD, LLC | 2006-05-25 | — | — | US | disclosed |
| WO-2006014484-A2 | METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS | SURMODICS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| WO-2002053132-A1 | WATER-SOLUBLE POWDERY OR GRANULAR COMPOSITIONS BASED ON PHENANTHRIDINES AND THEIR USES | VIRBAC S.A. (FR) | 2002-07-11 | — | — | WO | disclosed |
| WO-2002012194-A1 | PHENANTRIDINE DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT | AVENTIS PHARMA S.A. (FR) | 2002-02-14 | — | — | WO | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
| EP-0193414-A2 | Liposomes, process for their preparation and compositions containing them | Fluck, David John (ZW) | 1986-09-03 | — | — | EP | disclosed |
| US-4407800-A | TRYPANOCIDES | UNIVERSITY OF VIRGINIA ALUMNI PATENTS FOUNDATION (US) | 1983-10-04 | — | — | US | disclosed |
| EP-0006752-B1 | COMPOSITIONS FOR THE TREATMENT OF CHRONIC TRYPANOSOMIASIS INFECTIONS | MERCK & CO. INC. (US) | 1982-12-22 | — | — | EP | disclosed |
| US-4269830-A | ADMINISTERING A 5-NITROIMIDAZOLE COMPOUND AND BERENIL, 4,4'-/DIZAOAMINO/DIBENZAMIDINE DIACETURATE | MERCK & CO., INC. (US) | 1981-05-26 | — | — | US | disclosed |
| EP-0006752-A1 | Compositions for the treatment of chronic trypanosomiasis infections | MERCK & CO. INC. (US) | 1980-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320245-A1 | Nucleoside Analogues for the Treatment of Parasitic Infections | PNP, TYMP, NUDT1 | ACHE 943/4885MEN1 2607/4885BLM 275/4885 |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | ACHE 16/4885MEN1 3687/4885BLM 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.